These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 8397225

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Vitamin D receptor and PCNA expression in severe parathyroid hyperplasia of uremic patients.
    Wang X, Sun B, Zhou F, Hu J, Yu X, Peng T.
    Chin Med J (Engl); 2001 Apr; 114(4):410-4. PubMed ID: 11780466
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Adrenomedullin immunoreactivity tissue distribution in parathyroids of the patients with primary hyperparathyroidism.
    Letizia C, Ricci F, De Toma G, Cianci R, Alo P, Celi M, Panzironi G, Mingazzini PL, D'Erasmo E, Mazzuoli GF.
    Horm Metab Res; 2004 Jul; 36(7):480-4. PubMed ID: 15305232
    [Abstract] [Full Text] [Related]

  • 7. Parathyroid glands in uraemic patients with refractory hyperparathyroidism: histopathology and p53 protein expression analysis.
    Martin LN, Kayath MJ, Vieira JG, Nosé-Alberti V.
    Histopathology; 1998 Jul; 33(1):46-51. PubMed ID: 9726048
    [Abstract] [Full Text] [Related]

  • 8. 1,25-dihydroxyvitamin D3 and 22-oxacalcitriol prevent the decrease in vitamin D receptor content in the parathyroid glands of uremic rats.
    Denda M, Finch J, Brown AJ, Nishii Y, Kubodera N, Slatopolsky E.
    Kidney Int; 1996 Jul; 50(1):34-9. PubMed ID: 8807569
    [Abstract] [Full Text] [Related]

  • 9. Vitamin D in normal and pathological parathyroid glands: new prospects for treating hyperparathyroidism (review).
    Buchwald PC, Westin G, Akerström G.
    Int J Mol Med; 2005 Apr; 15(4):701-6. PubMed ID: 15754035
    [Abstract] [Full Text] [Related]

  • 10. Cardiovascular disease in chronic kidney failure: the role of VDR activators.
    Wu-Wong JR, Tian J, Nakane M, Ma J, Fey TA, Kroeger P, Fryer RM, Reinhart GA.
    Curr Opin Investig Drugs; 2006 Mar; 7(3):206-13. PubMed ID: 16555680
    [Abstract] [Full Text] [Related]

  • 11. The vitamin D hormone and its nuclear receptor: molecular actions and disease states.
    Haussler MR, Haussler CA, Jurutka PW, Thompson PD, Hsieh JC, Remus LS, Selznick SH, Whitfield GK.
    J Endocrinol; 1997 Sep; 154 Suppl():S57-73. PubMed ID: 9379138
    [Abstract] [Full Text] [Related]

  • 12. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
    Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF.
    Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
    [Abstract] [Full Text] [Related]

  • 13. Cross-talk between vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling in melanoma cells.
    Sertznig P, Dunlop T, Seifert M, Tilgen W, Reichrath J.
    Anticancer Res; 2009 Sep; 29(9):3647-58. PubMed ID: 19667161
    [Abstract] [Full Text] [Related]

  • 14. Parathyroid cell growth in patients with advanced secondary hyperparathyroidism: vitamin D receptor, calcium sensing receptor, and cell cycle regulating factors.
    Tokumoto M, Taniguchi M, Matsuo D, Tsuruya K, Hirakata H, Iida M.
    Ther Apher Dial; 2005 Aug; 9 Suppl 1():S27-34. PubMed ID: 16109139
    [Abstract] [Full Text] [Related]

  • 15. Vitamin D receptor as a candidate tumor-suppressor gene in severe hyperparathyroidism of uremia.
    Brown SB, Brierley TT, Palanisamy N, Salusky IB, Goodman W, Brandi ML, Drüeke TB, Sarfati E, Ureña P, Chaganti RS, Pike JW, Arnold A.
    J Clin Endocrinol Metab; 2000 Feb; 85(2):868-72. PubMed ID: 10690903
    [Abstract] [Full Text] [Related]

  • 16. 1Alpha,25-dihydroxy-3-epi-vitamin D3, a natural metabolite of 1alpha,25-dihydroxyvitamin D3, is a potent suppressor of parathyroid hormone secretion.
    Brown AJ, Ritter C, Slatopolsky E, Muralidharan KR, Okamura WH, Reddy GS.
    J Cell Biochem; 1999 Apr 01; 73(1):106-13. PubMed ID: 10088729
    [Abstract] [Full Text] [Related]

  • 17. Organ distribution of aluminium in uremic rats: influence of parathyroid hormone and 1,25-dihydroxyvitamin D3.
    Hirschberg R, von Herrath D, Voss R, Bossaller W, Mauelshagen U, Pauls A, Schaefer K.
    Miner Electrolyte Metab; 1985 Apr 01; 11(2):106-10. PubMed ID: 3838793
    [Abstract] [Full Text] [Related]

  • 18. 1,25-(OH)2D receptors are decreased in parathyroid glands from chronically uremic dogs.
    Brown AJ, Dusso A, Lopez-Hilker S, Lewis-Finch J, Grooms P, Slatopolsky E.
    Kidney Int; 1989 Jan 01; 35(1):19-23. PubMed ID: 2540371
    [Abstract] [Full Text] [Related]

  • 19. The genetic background of uremic secondary hyperparathyroidism.
    Aucella F, Morrone L, Stallone C, Gesualdo L.
    J Nephrol; 2005 Jan 01; 18(5):537-47. PubMed ID: 16299679
    [Abstract] [Full Text] [Related]

  • 20. Overproduction and secretion of a novel amino-terminal form of parathyroid hormone from a severe type of parathyroid hyperplasia in uremia.
    Arakawa T, D'Amour P, Rousseau L, Brossard JH, Sakai M, Kasumoto H, Igaki N, Goto T, Cantor T, Fukagawa M.
    Clin J Am Soc Nephrol; 2006 May 01; 1(3):525-31. PubMed ID: 17699255
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.